These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Emerging treatment options for patients with castration-resistant prostate cancer. George D; Moul JW Prostate; 2012 Feb; 72(3):338-49. PubMed ID: 21748753 [TBL] [Abstract][Full Text] [Related]
4. New and emerging agents for the treatment of castration-resistant prostate cancer. Higano CS; Crawford ED Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657 [TBL] [Abstract][Full Text] [Related]
5. New developments in castrate-resistant prostate cancer. Shore N; Mason M; de Reijke TM BJU Int; 2012 Jun; 109 Suppl 6():22-32. PubMed ID: 22672122 [TBL] [Abstract][Full Text] [Related]
6. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712 [TBL] [Abstract][Full Text] [Related]
7. New agents for prostate cancer. Agarwal N; Di Lorenzo G; Sonpavde G; Bellmunt J Ann Oncol; 2014 Sep; 25(9):1700-1709. PubMed ID: 24658665 [TBL] [Abstract][Full Text] [Related]
8. Emerging novel therapies for advanced prostate cancer. Osanto S; Van Poppel H Ther Adv Urol; 2012 Feb; 4(1):3-12. PubMed ID: 22295041 [TBL] [Abstract][Full Text] [Related]
9. Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Abdulla A; Kapoor A Can Urol Assoc J; 2011 Apr; 5(2):120-33. PubMed ID: 21470540 [TBL] [Abstract][Full Text] [Related]
10. Novel molecular targets for the therapy of castration-resistant prostate cancer. Agarwal N; Sonpavde G; Sternberg CN Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376 [TBL] [Abstract][Full Text] [Related]
11. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N; Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502 [TBL] [Abstract][Full Text] [Related]
12. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735 [TBL] [Abstract][Full Text] [Related]
13. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. Payne H; Bahl A; Mason M; Troup J; De Bono J BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837 [TBL] [Abstract][Full Text] [Related]
14. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Suzman DL; Antonarakis ES Ther Adv Med Oncol; 2014 Jul; 6(4):167-79. PubMed ID: 25057303 [TBL] [Abstract][Full Text] [Related]
17. Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges. Massari F; Maines F; Modena A; Brunelli M; Bria E; Artibani W; Martignoni G; Tortora G Anticancer Agents Med Chem; 2013 Jul; 13(6):872-86. PubMed ID: 23272970 [TBL] [Abstract][Full Text] [Related]